Tracking chemotherapy's effects on secondary cancers.
Vicki
V
Brower
D000293:Adolescent; D018943:Anthracyclines / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects; D020022:Genetic Predisposition to Disease; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000453:epidemiology*; D008558:Melphalan / Q000009:adverse effects; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000453:epidemiology* / Q000235:genetics; D018426:SEER Program; D014481:United States / Q000453:epidemiology; D055815:Young Adult
D018943:Anthracyclines; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D008558:Melphalan